Dr. Wang on Managing AEs Related to BTK Inhibitors

Michael Wang, MD
Published: Wednesday, Sep 26, 2018



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events (AEs) related to BTK inhibitors in the treatment of patients with mantle cell lymphoma (MCL).

A common AE related to BTK inhibition is atrial fibrillation. Wang says the heart is the most dynamic organ in the body, beating at a rate of 80 times per minute. Any slight interference with the heart’s function can cause a person to lose consciousness, and it can become fatal. Atrial fibrillation is something that needs to be treated effectively and aggressively. About 4% to 10% of patients with MCL who are treated with ibrutinib (Imbruvica) will develop atrial fibrillation, Wang says.

Whenever the slightest sign of atrial fibrillation arises, Wang says he stops BTK inhibition immediately and sends the patient to a cardiologist. He concludes that more work needs to be done to catch this condition earlier.
SELECTED
LANGUAGE


Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events (AEs) related to BTK inhibitors in the treatment of patients with mantle cell lymphoma (MCL).

A common AE related to BTK inhibition is atrial fibrillation. Wang says the heart is the most dynamic organ in the body, beating at a rate of 80 times per minute. Any slight interference with the heart’s function can cause a person to lose consciousness, and it can become fatal. Atrial fibrillation is something that needs to be treated effectively and aggressively. About 4% to 10% of patients with MCL who are treated with ibrutinib (Imbruvica) will develop atrial fibrillation, Wang says.

Whenever the slightest sign of atrial fibrillation arises, Wang says he stops BTK inhibition immediately and sends the patient to a cardiologist. He concludes that more work needs to be done to catch this condition earlier.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x